Fang et al. [31] examined inoperable NSCLC patients undergoing first-line immunotherapy plus chemotherapy and found that HALP did not significantly predict PFS (P ═ 0.771) or OS (P ═ 0.996), which differed from our findings. The gene discussed is NAT10; the disease is non-small cell lung carcinoma.